JanOne sees every day as an opportunity for fresh ideas to end the opioid epidemic, the worst drug crisis in our nation’s history.
As a NASDAQ-listed company, JanOne draws private-sector resources into this urgent fight. We seek innovative treatments—focusing on developing revolutionary, non-addictive drugs that kill pain, not people.
Featured on America This Week was JanOne’s advisory board chair Dr. Chris Kevil and pain expert Dr. Amol Soin. JanOne’s drug candidate for peripheral artery disease and its non-addictive pain relieving potential may reduce the need for opioid prescriptions https://janone.com/janone-scientific-advisory-board-chair-and-leading-pain-expert-featured-on-abc-7-wjla-america-this-week/